Human stem-cell-derived extracellular vesicles (EVs) are currently being investigated for cellfree therapy in regenerative medicine applications, but their biodistribution and tropic properties for homing to injured tissues are largely unknown. Here, we labeled EVs with magnetic nanoparticles to create magneto-EVs that can be tracked by magnetic resonance imaging (MRI).
Introduction
Extracellular vesicles (EV) are small membranous blebs or vesicles released from nearly all cell types that function as important messengers and mediators for intercellular communication in a diverse range of biological processes (1) . Depending on their biogenesis (2) , EVs are typically classified into exosomes (50-150 nm in diameter) or microvesicles (50-500 nm in diameter).
Exosomes are derived from specialized intracellular compartments, i.e., endosomes or multivesicular bodies (MVBs), while microvesicles are shed directly from the plasma membrane.
When reaching recipient cells that are either in the immediate vicinity or at a distance, EVs fuse with them to transmit cargo (e.g., proteins, messenger RNA, microRNA, and lipids) and elicit biologic changes in recipient cells (3) . In stem cell research, increasing evidence shows that EVs are essential for stem cells to protect or regenerate injured cells, presumably through an EVmediated paracrine effect (4, 5) . This has led to the use of stem cell-derived EVs alone for cellfree therapy (6, 7) . Indeed, compared to parental mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs), human stem cell-derived EVs are considered to be a safer and more effective regenerative medicine approach for treating many otherwise untreatable diseases such as kidney injury (8) (9) (10) (11) and cardiac disease (12, 13) . Despite the appeal and potential impact of EV-based therapies, there are currently no clinic-ready methods for noninvasively tracking their bio-distribution and uptake to guide, optimize, and monitor treatment.
Noninvasive in vivo imaging approaches are needed that can track the distribution and fate of administered EVs over time. Importantly, such methods could be used to assess the quantity of administered EVs in the organs to be treated, which may be predictive of a therapeutic response.
Before this, EV imaging and tracking methods can serve as a guide to direct the development, optimization, and implementation of EV-based therapeutics. To date, considerable effort has been devoted to develop EV tracking methods using fluorescence imaging (14, 15) , bioluminescence imaging (16) , single-photon emission computed tomography (SPECT) (17) , positron emission tomography (PET) (18) , computed tomography (CT) (19, 20) , magnetic resonance imaging (MRI) (21, 22) , and magnetic particle imaging (23) . Among them, MRI is an appealing imaging modality that is used widely in the clinic and has excellent soft-tissue contrast without using ionizing radiation. To the best of our knowledge, there are only two reports on in vivo MRI-based EV-tracking studies. In the study reported by Busato et al (21) , superparamagnetic iron oxide (SPIO) particles were introduced into the parent cells (adipose stem cells) and the EVs secreted from these cells were then collected. While this approach doesn't require a purification procedure to remove free SPIO, the labeling efficiency was unfortunately found to be low, making in vivo tracking of EVs challenging due to the inherently low sensitivity of MRI. Hu et al. used electroporation to load SPIOs into EVs and subsequently purified them by ultracentrifugation (22) . While this approach provides high labeling, ultracentrifugation is not an efficient method to remove free naked SPIO nanoparticles and induces SPIO aggregation when pelleting. Hence, an efficient technology to obtain highly purified SPIO-labeled EVs is still an unmet need.
The aim of this study was to first develop a platform technology for preparing highly purified magnetically labeled EVs (magneto-EVs) and then to test in vivo MRI tracking of their wholebody distribution. We chose to use iPSC-derived EVs because iPSCs are more amenable to generate therapeutic EVs to protect or repair injury, which has been demonstrated in a few preclinical studies (24) . We have recently shown that human iPSCs can be cultured infinitely in chemically defined medium (free of exogenous EVs from serum or other biological sources) and
produce EVs markedly higher than other types of stem cells (25) . Considering that stem cell derived EVs lack nuclei, iPSC-derived EVs are attractive without the concerns of genetic instability and tumorigenicity associated with the administration of whole iPSCs (26, 27) .
Moreover, individualized autologous iPSCs can be generated from a single blood draw or skin sample from the same patient to minimize immunogenicity and ethical concerns (26) . Using different animal tissue injury models, we show here that the temporal-spatial distribution of magnetically labeled iPSC-derived EVs can be assessed quantitatively in vivo with MRI.
Results

Magnetic labeling of EVs and purification
To prepare "sticky" magnetic nanoparticles, we first synthesized surface-modified SPIO nanoparticles by conjugating them with hexa-histidine peptides (6´His) using the synthetic route shown in Fig. 1A . With His-tags on the surface, which was confirmed by Fourier-transform infrared spectroscopy ( Fig. S1) , SPIO nanoparticles can selectively bind to Ni 2+ immobilized nitrilotriacetic acid (NTA) agarose resins (Ni-NTA) ( Fig. 1B) . This complex has a distinct color ( Fig. S2) , where the Ni-NTA column eluted with SPIO-COOH (no His tag) showed no color change whereas the one eluted with SPIO-His changed from light blue to brown.
The labeling and purification procedures of magneto-EVs are illustrated in Fig. 1C . In brief, the synthesized SPIO-His nanoparticles were first loaded into purified EVs by electroporation as described previously (25) . The resulting solution containing a mixture of free SPIO-His and magneto-EVs was purified using a Ni-NTA column. Quantitative analysis of iron content in the solution pre-and post-elution revealed that the Ni-NTA column was able to remove 97.4% of unincorporated SPIO-His with minimal loss of EVs (~5.4% as measured by nanoparticle tracking analysis). The average size was measured using dynamic light scattering (DLS) to be 43.9±16.5 nm, 248.2±107.2 nm, 45.6±15.9 nm, and 292.8±113.0 nm, for SPIO-His, EVs, unpurified magneto-EVs, and purified magneto-EVs, respectively (Fig. 1D) . The size distribution of magneto-EVs closely resembled that of unlabeled EVs, indicating the efficient removal of unencapsulated SPIO-His particles. Labeling and purification were verified by transmission electron microscopy (TEM) ( Fig. 1E) , which showed no unencapsulated SPIO-His particles in the purified solution. TEM demonstrated that many EVs contained multiple SPIO-His particles. Moreover, the incorporation of magnetic particles allowed enrichment of magneto-EVs using a magnetic force ( Fig. 1F) .
In vitro MRI confirmed the hypointense contrast of magneto-EVs ( Fig. 1G) . At 9.4 T and 37 o C, the R2 enhancement was determined to be 1.83 s -1 per 10 8 /mL EVs, which is equivalent to an r2 relaxivity of 1.1´10 10 s -1 mM -1 per EV (10 8 /mL EVs = 16.7 pM) or 659 s -1 mM -1 Fe (10 8 /mL EVs contain 155 ng/mL Fe as measured by ICP-OES). From this, we estimated the in vivo detection limit to be approximately 8.76´10 7 EVs/mL EVs kidney tissue (having an inherent R2 of 32.03 s -1 at 3T(28)), assuming a 5% MRI signal change. 
In vivo MRI of iPSC-EV uptake in an injured kidney model
We first assessed the distribution of magneto-EVs in an lipopolysaccharides (LPS)-induced acute kidney injury (AKI) model, a well-established rodent model associated with severe systemic inflammation and irreversible kidney damage within 24-48 hours (29, 30) . As SPIO nanoparticles strongly distort the local magnetic field and result in a much quicker T2* decay of protons in nearby water molecules (31, 32) , the dynamic uptake of SPIO-containing magneto-EVs could be readily detected using T2*-weighted (T2*w) MRI (Supplementary video S1) in which magneto-EVs appear as hypointense spots. As shown in Fig. 2A , either SPIO-His particles or magneto-EVs were i.v. injected into uninjured control or LPS-AKI mice and the MRI signal was monitored dynamically for 30 minutes after injection. The 30-minute window was chosen because the blood half-life of EVs has been reported to be 2-4 minutes only (33) . P=0.0254). The ΔR2* in the LPS-AKI group after SPIO-His injection was also higher than that in the normal control group (46.0 vs, 14.3 s -1 , P=0.0035). In addition, we calculated the dynamic ΔR2* values in the kidney for each group (Fig. S3B ), confirming the differential kidney uptake dynamics for LPS-AKI mice injected with magneto-EVs versus all other groups.
To determine whether magneto-EVs can be taken up by the liver non-specifically, as is the case (35) , we further analyzed liver contrast-enhancement in both LPS-AKI and uninjured control mice ( Fig. S3A) . As shown in Fig. 2J , none of the groups showed significantly different ΔR2* values at 30 min after injection of magneto-EVs or SPIO-His particles. Similar dynamic liver uptake patterns were observed among these groups ( Fig.   S3C ), suggesting that there is negligible non-specific liver uptake of iPSC-EVs. 
High-resolution ex vivo MRI of iPSC-EV uptake in an injured kidney model
To study the biodistribution of magneto-EVs and naked SPIO-His particles in kidneys in more anatomic detail, we performed high resolution three-dimensional (3D) ex vivo MRI on fixed kidney samples that were excised at 30 min after magneto-EV or SPIO-His injection. Fig.3A shows representative kidney T2*w images of LPS-AKI mice injected with magneto-EVs, SPIO-His particles, and saline, respectively. Only the kidneys from mice receiving magneto-EVs demonstrated a high number of hypointense spots and streaks dispersed throughout the renal cortex ( Fig. 3A, left) . In contrast, kidneys of mice injected with SPIO-His particles showed far fewer black spots (Fig. 3A, middle) , similar to the kidney without SPIO-His injection (Fig. 3A,   right) . The presence of black hypointensities in the last two groups may be due to the LPSinduced hemorrhage (H&E stain, Fig. S4 ). 3D reconstruction of hypointense voxels revealed that magneto-EVs distributed throughout the whole kidney, with preferential accumulation in the cortex (Fig. 3B , full 3D visualization shown in supplementary video 3). Quantitative analysis showed that approximately 28.1% of the cortex of AKI mice injected with magneto-EVs contained hypointensities ( Fig. 3C) , significantly higher than those injected with SPIO-His particles alone (12.5%, P<0.0001) or saline (11%, P<0.0001). Accumulation of magneto-EVs in the cortex was confirmed by Prussian blue staining for iron ( Fig. 3D) , where the tissue distribution of magneto-EVs showed a good agreement with that seen on ex vivo MRI.
Furthermore, immunostaining for VCAM-1, a vascular inflammation marker, showed that LPS-AKI kidneys exhibited higher VCAM-1 expression in the cortex compared to the medulla (Fig.   3E ). Prussian blue-positive iron also co-localized with dilated proximal tubules as shown on Periodic acid-Schiff (PAS) staining ( Fig. 3F) , with the tubular damage being a hallmark of the LPS-AKI model (36) . In contrast, kidneys from control mice injected with either magneto-EVs or SPIO-His particles exhibited fewer hypointense areas, and those hypointense areas on T2*w images ( Fig. 3G ) correlated well with the negative Prussian blue staining (Fig. 3H) .
The accumulation of iPSC-derived EVs in the injury sites resulted in an observable therapeutic effect. A single dose of 2´10 9 EVs was injected at 0 (LPS co-injection), 3, or 24 h after LPS injection ( Fig. 3I) . Compared to vehicle control (PBS), only the magneto-EV/LPS co-injection resulted in a statistically significant improvement of survival rate (n=5, P=0.0023, unpaired twotailed Student's t-test). The lack of improvement of survival when magneto-EVs were injected at 3 and 24 hours is likely due to the rapid progression of kidney injury in the LPS-AKI model.
Indeed, without treatment, the animal loss at 24 and 48 hours was 50 and 100%, respectively.
To assess whether the accumulation of magneto-EVs in the injured kidney and their subsequent protective effect is attributed to their stem cell origin, we also isolated EVs from fetal bovine serum (FBS) and injected them into LPS-AKI mice using the same protocol as for iPSC-EVs.
The ex vivo MRI results ( Fig. 3J) showed that a high quantity of FBS-EVs accumulated in the cortex similarly to iPSC-EVs, suggesting that the accumulation of magneto-EVs in the injured sites may not be specific to their cell origin. However, despite their similar uptake pattern FBS-EVs did not generate protection against the LPS-induced kidney injury (Fig. 3K, P=0.2055 ), suggesting that the therapeutic effects are specific to the cell origin of the EVs. 
Biodistribution of iPSC-EVs in other experimental injury models
We further assessed the ability to track magneto-EVs in two other animal injury models. First, kidneys were subjected to a unilateral ischemia-reperfusion injury (IRI) (Fig. 4A ). An acute injury in the right kidney was obtained by occluding the blood supply for 45 min, with the untreated left kidney as control. iPSC-derived magneto-EVs were administered i.v. at the same time when reperfusion started. As shown in Figs. 4B,C, a higher EV uptake was observed in the injured kidneys but not the contralateral ones (∆R2*= 30.1 s -1 and 15.7 s -1 , P=0.04, two-tailed paired Student's t-test, n=4). The biodistribution pattern of magneto-EVs homing to the injury site was distinct from the AKI mice induced by LPS injection. Both the ex vivo MRI (Fig. 4E) and histology ( Fig. 4F) showed more magneto-EVs accumulating in the medulla than the cortex, representing the difference in the primary site of injury between these two experimental models.
We then applied our technology to study the distribution of i.v.-injected magneto-EVs in an IRinjured mouse heart, which was induced through the ligation of the left anterior descending (LAD) coronary artery for 35 min, followed by reperfusion (37) (Figs. 5A,B) . The MRI results revealed that magneto-EVs accumulated selectively at the injury sites (Figs. 5C,D) . The distribution of EVs followed an alignment with the injured myocardium ( Fig. 5E) , which was confirmed by high resolution ex vivo MRI ( Fig. 5F) and Prussian blue staining (Fig. 5G) . 
Discussion
The primary aim of our study was to develop a non-invasive MRI tracking method for sensitive and accurate determination of the pharmacokinetics and biodistribution of therapeutic EVs in living subjects. Increasing evidence now supports the use of stem cell-derived EVs for regeneration of injured tissue with similar or even better therapeutic effects as compared to their parental cells, and without some of the limitations and risks associated with whole cell therapybased approaches (13, 38) . However, in order to optimize the use of EVs as therapeutic agents, much needs to be learned about their pharmacokinetics and whole-body distribution as related to their dose, injection route, and cell origin. To this end, the availability of a whole-body noninvasive imaging tracking method is critical. Indeed, for whole cell therapy, MRI has shown to be invaluable to monitor the spatiotemporal fate of injected cells in numerous preclinical studies and a few clinical studies (39) (40) (41) . Our current study demonstrates that human iPSC-derived magneto-EVs produce a sufficiently strong MRI signal to allow for their in vivo tracking in the injured kidney and heart, in several different animal injury models.
One of the most challenging technical hurdles for imaging EVs is their small size. The typical diameter of EVs is less than 200 nm, making their volume approximately five orders of magnitude (1.25´10 5 times) smaller than that of their parental cells (diameter ~10 µm). We used SPIO nanoparticles as they have been shown to be the most sensitive MRI contrast agent (42) . In addition, we used the smallest commercially available SPIO nanoparticles with a 5 nm core size (~ 46 nm hydrodynamic size) to maximize the encapsulation rate. The TEM results showed that a few SPIO nanoparticles were loaded into a single EV, increasing detection sensitivity. The in vivo studies showed that a relatively low dose of 1.5 µg iron per mouse (0.67 µmol Fe/kg body weight) resulted in high MRI contrast allowing visualization of the accumulation of i.v.-injected magneto-EVs in injured tissue. In comparison, as an imaging agent for evaluation of renal function, SPIO has been used at a dose level of 60 µmol Fe/kg (43) , two orders of magnitude higher than the dose used in the present study. Indeed, the estimated in vivo detection limit is only 8.76´10 7 EVs/mL by our in vitro data. With such a high detectability, we were able to assess the biodistribution of iPSC-derived EVs using a low level of dose (i.e., 1´10 9 EVs or 10 µg proteins per mouse, assuming the protein content is 1 µg protein per 1´10 8 EVs (44)), which is lower than those used for SPECT (i.e., 29- 64 µg (14, 17) ), optical imaging (i.e., 2.5-200 μg (7, 14) ), and CT (i.e., 28 μg (19)). To the best of our knowledge, there is no MRI studies reported using i.v. injection. While a report showed that local injection of 5´10 8 EVs could result in a detectable MRI signal (21) , higher doses have to be used to achieve a reliable MRI signal, i.e., 25 µg in the same study and 50 µg for lymph node imaging with EVs injected in foot pads (22) .
Compared to all those pervious imaging methods, our technology provides a high sensitivity that permits MRI tracking of EVs in vivo.
Our platform technology for preparing highly purified magnetically labeled EVs is simple but efficient, and potentially useful for other nanoparticles and ligand-binding systems. Previous studies used commercially available SPIO nanoparticles by either pre-incubation of the parental cells with SPIOs, followed by the collection of labeled EVs(21), or ii) direct labeling with SPIOs using electroporation (22, 45) . The first approach often suffers from low labeling efficiency as only a portion of EVs secreted by the labeled cells containing SPIOs, whereas the second approach relies on the use of sophisticated and time consuming (i.e., 2 hours(45)) purification steps to remove unencapsulated SPIO. In contrast, our approach employs surface-modified SPIOs and the corresponding purification procedure is relatively simple, less equipmentintensive, and faster (~minutes), providing an efficient way to prepare highly purified magneto-EVs with minimal EV loss during the purification steps. The resulting magneto-EVs have a high purity, hence allowing accurate detection and measurement of the spatiotemporal quantity and distribution of administrated EVs, without false positives (i.e., non-encapsulated SPIOs).
Using the MRI signal of the magneto-EVs, we were able to detect the dynamic uptake and biodistribution of EVs in different tissues of three disease models non-invasively. In the LPS-AKI mice, the MRI results showed that magneto-EVs accumulated in the injured kidney at a much higher level than in uninjured controls. The distribution of EVs colocalized well with the injured proximal tubules in the cortex similar as previously reported for MSC-derived EVs in a cisplatin-induced AKI model (46) . The accumulation of EVs in the injured areas was further confirmed in an IRI kidney model, where iPSC-derived EVs preferentially accumulated in damaged glomeruli in the medullar regions, in good agreement with previous reports on MSCs (28, 47) . In addition, the accumulation of EVs provided significant protective effects and increased survival in the lethal LPS-AKI model. Moreover, our MRI results revealed similar distribution patterns for EVs isolated from iPSCs and FBS, suggesting that accumulation of EVs itself in the injured sites may not be attributable to the cell origin of EVs. However, only iPSCderived EVs but not FBS-EVs produced a strong protective effect and improved the survival of mice with injured kidneys, supporting the notion that the therapeutic effects are attributed to the stem cell origin. Finally, unlike other synthetic nanoparticles, our MRI results revealed only a moderate uptake of EVs in the liver, even at a lower level than in the injured kidney, suggesting that EVs may be a promising new nanoparticulate drug carrier to bypass non-specific liver uptake and consequently improve drug delivery.
Conclusions
We developed a platform technology for preparing magneto-EVs for in vivo MRI tracking. A high efficiency of purified magnetically labeled EVs could be achieved using SPIO particles functionalized with His-tags, while non-encapsulated particles could be easily removed using a Ni-NTA column. This strategy allowed successful preparation of magneto-EVs derived from either human iPSC or FBS. Highly purified labeled EVs are essential to mitigate false positives (i.e., non-encapsulated SPIOs) for accurate detection and measurement of their spatiotemporal distribution. Magneto-EVs produced sufficient MRI signal to allow MRI detection of injected EVs in injured organs, including kidney and heart, correlating well with the histological assessment and therapeutic outcome in the LPS-AKI model. Our technology represents a novel tool for in vivo tracking of therapeutic EVs and for guiding their applications in EV-based regenerative medicine and possibly EV-based drug delivery.
Materials and Methods
Materials
Carboxyl SPIOs (SPIO-COOH, core diameter = 5 nm) was purchased from Ocean Nanotech (Springdale, AR). Hexa-histidine peptide was purchased from GeneScript (Springdale, AR, USA). 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), sulfo-N-hydroxysuccinimide (sulfo-NHS) and Ni-NTA were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
Human iPSCs were programmed from blood cells of a healthy male donor (48) , cultured in 6well plates coated with vitronectin (Gibco, Calsbad, CA), and maintained in Essential 8 (E8) medium (Gibco) supplemented with 10 µM Y-27632 dihydrochloride (Stem Cell Technologies, Vancouver, Canada at 37°C in a humidified atmosphere of 5% CO2 and 95% air. The culture medium was changed daily after gently washing the cells with 10 mM PBS, pH=7.4. Cells were passaged at 80%-90% confluence using TrypLE™ Express Enzyme (Gibco) supplemented with 10 µM Y-27632 dihydrochloride. Cells were routinely checked for mycoplasma contamination.
Synthesis of SPIO-His
Fifty microliters of SPIO-carboxyl (2 mg/mL) was mixed with 100 µg EDC (10 mg/mL) and 100 µg NHS (10 mg/mL), and 100 µL MES buffer (pH=6.0). The solution was shaken for 30 min.
One mg of peptide (25 mg/mL in dd H2O) was then added, followed by adding 200 µL 10 mM PBS, pH=7.4. The pH of the solution was then adjusted to 7.4, followed by shaking for 2 h. The product was dialyzed, lyophilized and reconstituted to 2 mg Fe/mL.
Collection, purification and enrichment of EVs
To acquire concentrated EVs, medium was harvested from multiple passages of iPSC culture and concentrated. Culture medium in 50 mL tubes was centrifuged for 10 min at 300 g followed by another 10 min at 2,000 g at 4 °C to remove cells and debris. The medium was then concentrated to 200 µL using an Amicon ultra-15 filter column and an Ultracel-100 membrane by centrifugation at 4,000 g for 20 min (MilliporeSigma, Billerica, MA, USA). Then, 0.5 mL of the concentrated medium was loaded to a qEV column (iZON, Cambridge, MA, USA) and eluted with PBS in 500 µL fractions with collection of the 7-9 fractions. This procedure removes small medium molecules from the concentrate. Purified EVs (about 2.4 mL elute from a total of 300 mL medium) were further concentrated six times using a qEV column to a final volume of 0.4 mL. To further enrich magneto-EVs, the microcentrifuge tube containing purified magneto-EVs was fixed upright on a 1-inch cube Neodymium magnet (CMS magnetics, Garland, TX, USA) overnight and the pelleted magneto-EVs were resuspended in the desirable volume of PBS.
Isolation and purification of FBS (catalog #F2442, Sigma-Aldrich) derived EVs were performed in a similar manner.
Electroporation of EVs
Fifty microliters of concentrated EVs (1.1´10 11 /mL) were mixed with 25 µL of 2 mg/mL SPIO-His. Electroporation was performed with a Gene Pulser Xcell Electroporation Systems (Biorad) using two pulses of 240 V/mm and 100 F Capacitance with a 1 mm cuvette. EVs were then transferred to a clean microcentrifuge tube and placed on ice for 1 h before Ni-NTA purification.
Purification of magneto-EVs
Ni-NTA columns were prepared by packing 1 mL Ni-NTA His•Bind resins (Sigma) into a 6-ml ISOLUTE® Single Fritted Reservoir column with 10 µm polyethylene frit (Biotage, Charlotte, NC, USA), followed by washing with 5 mL PBS. After electroporation, EVs (~75 µL) were resuspended in 200 µL PBS and then loaded onto a Ni-NTA column and gently shaken for 30 min. After the first elute was collected, the column was rinsed with 200 µL PBS. All elutes were collected using 1 mL microcentrifuge tubes.
The size and iron content of EVs was measured by dynamic light scattering (DLS, Nanosizer ZS90, Malvern Instruments) and by inductively coupled plasma optical emission spectroscopy (ICP-OES, Thermo iCAP 7600, ThermoFisher Scientific, Waltham, MA, USA), respectively. To estimate the loss of EVs during the purification procedure, the numbers of EVs before and after purification were measured using a nanoparticle tracking analysis (NTA) instrument (Zetaview, Particle Metrix, Germany) using a 488-nm laser and ZetaView 8.04.02 software.
Transmission electron tomography
Carbon-coated 400 mesh copper grids (Electron Microscopy Services, Hatfield, PA, USA) were placed on 30 µl drops of SPIO or EV samples for one minute. Grids were quickly washed with two drops of dH2O and blotted dry on a filter paper. Grids were stained for one minute with 2% uranyl acetate (Electron Microscopy Services) in dH20 and blotted dry. All imaging was performed with a Zeiss Libra 120 TEM operated at 120 KV and equipped with an Olympus Veleta camera (Olympus Soft Imaging Solutions GmbH, Münster, Germany).
Mouse models of acute kidney injury
All animal experiments were approved by our Animal Care and Use Committee. Male C57BL/6J mice (6-8 weeks of age) were acquired from Jackson Laboratories (Bar Harbor, ME, USA). The LPS-AKI model was established as described previously (29) by intraperitoneal (i.p.) administration of lipopolysaccharide (LPS, Sigma Aldrich) at a dose of 10 mg/kg. The IRI-AKI model was established according to a previously published procedure (49) . In brief, animals were anesthetized with 2% isoflurane and an incision was made in the back muscle and skin layer to expose the right kidney and the renal vascular pedicle was clamped using a microvessel clamp (#18052-03, Fine Science Tools, Foster City, CA, USA) for 45 min, followed by suture-closing the incisions.
Mouse model of heart ischemic and reperfusion injury (IRI)
Male C57BL/6J mice under induction anesthesia with 3-4% isoflurane received 0.03-0.07 mg/kg buprenorphine subcutaneously (s.c.). Isoflurane was then adjusted to 1-2% and 2 mg/kg succinylcholine was administered i.p. After 5 min, a left thoracotomy was performed in the 5th to 6th intercostal space. The pericardium was torn and the coronary artery was located. A piece of 7-0 prolene was tied around the coronary artery with a small piece of black polyethylene PE10 tubing (Braintree Scientific Inc., Braintree, MA, USA) under the suture. Occlusion was performed for 35 min. During occlusion, ribs were closed with one single 5-0 silk suture and the skin was closed with a bulldog clamp (Fine Science Tools, Foster City, CA, USA). At 5 min prior to ending the occlusion, the chest was reopened carefully and the sutures were removed.
Ribs and skin were closed with 5-0 silk. Mice were allowed to regain consciousness and a second dose of buprenorphine at the dose of 0.06-0.075 mg/kg was administered s.c.
In vitro MRI
Samples of SPIO-COOH, SPIO-His, unlabeled and labeled EVs were prepared at different concentrations in 10 mM PBS, pH=7.4 and transferred to 5 mm glass NMR tubes, and then combined for MRI measurements on a Bruker 9.4 Tesla vertical bore scanner equipped with a 20 mm birdcage transmit/receive coil. T2 relaxation times were measured using the Carr-Purcell-Meiboom-Gill (CPMG) method at room temperature as previously described (50) . The acquisition parameters were: TR/TE=25 s/4.3 ms, RARE factor=16, matrix size=64´64, in-plane resolution=0.25´0.25 mm and slice thickness=2 mm. Each T2w image took approximately 1'40'' to acquire. The T2 relaxivities (r2) were calculated based on mean R2 (=1/T2) of each sample and their concentrations (c), using the following equation:
Where R2 0 represents the inherent water proton transverse relaxation rate.
In vivo MRI
All animal studies were performed on a 11.7T Biospec (Bruker) horizontal bore scanner equipped with a mouse brain surface array RF coil (receiver) and a 72 mm volume coil (transmitter). A 30-min dynamic scan was acquired using a fast low angle shot (FLASH) gradient echo sequence immediately before i.v. injection of 1´10 9 magneto-EVs or 1.5 µg SPIO-His (having the same iron amount as that in magneto-EVs) in 200 µL PBS. The acquisition parameters were: flip angle=25°, TR=800 ms, TE=5.8 ms, matrix size=256´128 and resolution=167´280 mm 2 . Before and 30 min after injection T2* maps were also acquired using a multiple gradient echo (MGE) pulse sequence with TR=800 ms and TE times of 2.6, 5.8, 9, 12.2, 15.4, 18.6, 21.8, and 25 ms.
After MRI, mice were euthanized by cervical dislocation under anesthesia and tissues of interest were collected and fixed in 4% paraformaldehyde solution for ex vivo MRI and histological analysis.
Ex vivo MRI
Excised organs (i.e., kidney, heart, and liver) were transferred to a 5 ml syringe filled with proton-free fluid Fomblin (Solvay Solexis, Inc., USA) and ex vivo high-resolution MRI was performed on a vertical bore 9.4T Bruker scanner equipped with a 15 mm birdcage transmit/receive volume coil. A three-dimensional FLASH sequence was used with TE=6 ms, TR=150 ms, matrix size=310´230´155, FOV=12´9´6 mm, resolution=0.039´0.039´0.039 mm, averages=5, and flip angle=15°. The total scan time was 6h43m12s.Amira 3D Visualization Software 5.4.3 (Visage Imaging Inc., Carlsbad, CA, USA) was used to quantify the areas of hypointense signal and to visualize the 3D distribution of magneto-EVs.
Histological analysis
Excised tissues were paraffin-embedded and sectioned at 5 µm thickness, and stained with Prussian blue and Periodic acid-Schiff (PAS). Sections were imaged using a Zeiss Axio Observer Z1 microscope (Zeiss, Oberkochen, Germany) and processed using Zen Pro software.
Effects of iPSC-EV treatment on LPS-induced AKI mice.
Five treatment groups were tested: 1) iPSC-EV was administered at the same time as LPS injection; 2) iPSC-EV was administered at 3 hours after LPS injection; 3) iPSC-EV was administered at 24 hours after LPS injection; 4) FSB-EV was administered at 3 hours after LPS injection; and 5) vehicle control (200 µL PBS) was administered at the same time as LPS injection. Five mice were randomly chosen for each group. For all EV treatment groups, 2´10 9 EVs in 200 µL PBS were administered i.v. through the tail vein. Animal survival was monitored for each group every day up to 6 days.
Statistical analysis
All data are presented as mean±s.e.m. GraphPad Prism version 8 (GraphPad Software Inc., San Diego, CA, USA) was used to perform statistical analysis. A unpaired two-tailed Student's t-test was used to compare the difference between two groups. Differences with P<0.05 were considered statistically significant. The Kaplan-Meier method was used to analyze animal survival data. 
